Abstract:Abstract Background: Radioimmunotherapy (RIT) of patients with solid tumors poses a challenge due to the slow blood clearance and delayed tumor uptake of directly radiolabeled antibodies that can cause high radiation exposure to normal tissues. Pretargeting techniques utilizing bispecific antibodies (bsmAbs) overcome these limitations by administering the tumor-targeting antibody and the radioactive payload sequentially. First, the bsmAb is injected and allowed to accumulate in the tumor. Once >95% bsmAbs have cleared from circulation, a small radioligand with high affinity to the bispecific antibody is administered. Due to its pharmacokinetic profile, the radioligand quickly binds to the tumor-trapped bsmAbs while excess radioligand is rapidly excreted by the kidneys. Thereby, high tumor/non-tumor ratios are achieved. Oxidized Macrophage Migration Inhibitory Factor (oxMIF) is the disease-related structural isoform of the pleiotropic cytokine MIF and is specifically present in tumor tissue. Here we show preclinical efficacy of an anti-oxMIF x anti-HSG (histamine-succinyl-glycyl) bsmAb designed for pretargeted RIT (PRIT). Methods: Infrared dye-labeled cON-05, an anti-oxMIF x anti-HSG bsmAb, was administered to Balb/c mice bearing subcutaneous CT26 cancer syngrafts to assess tumor uptake and retention by infrared imaging and its pharmacokinetics by ELISA. A PRIT regimen using cON-05 in conjunction with a Lu177-loaded di-HSG peptide was examined in Balb/c mice bearing subcutaneous (s.c.) CT26 colon cancer syngrafts and in Balb/c nude mice bearing s.c. CFPAC-1 pancreatic cancer xenografts. Results: Infrared dye-labeled cON-05 accumulated in the tumor and was retained for >7 days. cON-05 was found to clear from circulation following a biexponential decay with only 1-2% of the injected dose remaining in plasma after 3-5 days post-injection. Significant tumor regression and survival benefit (100% cON-05 vs. 0% vehicle) were achieved in mice bearing CT26 colorectal tumors, if cON-05 (5 mg/kg) was administered 3 days prior to applying Lu177-di-HSG. In the same model, when changing the pretargeting interval to 5 days, significant tumor growth inhibition (TGI; 29% and 44% on day 9) and survival benefit (15 and >21 days cON-05 vs. 9 days vehicle) could be demonstrated for 2.5 and 5 mg/kg cON-05. In a CFPAC-1 pancreatic cancer mouse xenograft model, 38% TGI on day 28 was achieved upon injection of 5 mg/kg cON-05 followed by Lu177-di-HSG 5 days later. Conclusion: cON-05 is a novel anti-oxMIF x anti-HSG bsmAb designed for PRIT. cON-05 shows good tumor penetration and retention and tumor growth inhibition in conjunction with Lu177-di-HSG peptide in colorectal and pancreatic cancer mouse models. PRIT with cON-05 might offer new options for patients with difficult-to-treat tumors (e.g., pancreatic, gastric, head & neck) Citation Format: Alexander Schinagl, Irina Mirkina, Alejandro Puchol Tarazona. Pretargeted radioimmunotherapy with a novel anti-oxMIF/HSG bispecific antibody and a Lu177-loaded HSG radioligand results in significant tumor regression in murine models of cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 585.

Advantage of the F(ab)'2 fragment over IgG for RIT and PRIT

Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses

Efficient α and β- radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model

Abstract 6030: Optimizing the therapeutic index of targeted α-particle radioimmuotherapy (TART) of HER2-positive breast cancer tumors in NRG mice with 225Ac-labeled trastuzumab

Metal-Free Cycloaddition Chemistry Driven Pretargeted Radioimmunotherapy Using α-Particle Radiation

Preclinical Aspects of [89Zr]Zr-DFO-Rituximab: A High Potential Agent for Immuno-PET Imaging

Radioimmunotheragnosis in Cancer Research

α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colon Cancer Xenografts

A general approach to reduce off-target radioactivity in vivo via Tetrazine-Knock-Out (TKO)

Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancer

Abstract 585: Pretargeted radioimmunotherapy with a novel anti-oxMIF/HSG bispecific antibody and a Lu177-loaded HSG radioligand results in significant tumor regression in murine models of cancer

Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting

Intranuclear Irradiation Inhibits Solid Tumor Growth by Upregulating Caspase8 and Activating Apoptosis

Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer

In vitro and in vivo evaluation of a tetrazine-conjugated poly-L-lysine effector molecule labeled with astatine-211

Panitumumab-DOTA-111In: An Epidermal Growth Factor Receptor Targeted Theranostic for SPECT/CT Imaging and Meitner-Auger Electron Radioimmunotherapy of Triple-Negative Breast Cancer

Two ⁹⁰Y-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy.

Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models

Radiotheranostic Agents in Hematological Malignancies

Synthesis of Site-Specific Radiolabeled Antibodies for Radioimmunotherapy Via Genetic Code Expansion.

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071